New drug tracking study launches for rare genetic cancer type

NCT ID NCT06672523

Recruiting now Knowledge-focused Sponsor: Bristol-Myers Squibb Source: ClinicalTrials.gov ↗

First seen Apr 28, 2026 · Last updated May 17, 2026 · Updated 5 times

Summary

This study looks at how a new drug (BMS-986504) moves through and leaves the body in people with advanced solid tumors that have a missing MTAP gene. Eight participants will receive a radioactive-labeled version of the drug so researchers can measure its levels in blood, urine, and stool. The goal is to understand how the drug is broken down and eliminated, not to test its effectiveness.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS WITH HOMOZYGOUS MTAP DELETION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Locations

Centro Integral Oncologico Clara Campal-Hospital HM Universitario Sanchinarro-START Madrid,
RECRUITING

Madrid, 28050, Spain

Contact Phone: •••-•••-••••
ICON / PRA Magyarország Kft. Fázis I-es Klinikai Farmakológiai Vizsgálóhely
RECRUITING

Budapest, 1076, Hungary

Contact Phone: •••-•••-••••
START Rioja, The START Center for cancer research
RECRUITING

Logroño, 26006, Spain

Contact Phone: •••-•••-••••

Conditions

Explore the condition pages connected to this study.

ADVANCED SOLID TUMORS WITH HOMOZYGOUS MTAP DELETION